TransMedics Group (NASDAQ:TMDX) Shares Up 5.9% – What’s Next?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) rose 5.9% during mid-day trading on Friday . The company traded as high as $143.30 and last traded at $142.55. Approximately 627,862 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 776,607 shares. The stock had previously closed at $134.57.

Analyst Ratings Changes

A number of research firms have commented on TMDX. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Oppenheimer boosted their price target on shares of TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday. Canaccord Genuity Group boosted their target price on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. increased their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Piper Sandler increased their price target on shares of TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group Trading Up 7.2%

The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.13 and a current ratio of 7.14. The firm has a market cap of $4.95 billion, a price-to-earnings ratio of 29.40 and a beta of 2.06. The business has a fifty day simple moving average of $133.45 and a 200-day simple moving average of $126.31.

Insider Buying and Selling at TransMedics Group

In related news, Director David Weill sold 5,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the sale, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of TransMedics Group by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock worth $404,549,000 after buying an additional 9,650 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in TransMedics Group by 11.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after purchasing an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the period. Geode Capital Management LLC boosted its position in shares of TransMedics Group by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after purchasing an additional 2,903 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after buying an additional 223,409 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.